Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
EBITDA valuation: for co’s up to $100Mil.Rev., is normally 5-7x EBITDA(Earnings before interest taxes depreciation and amortization)
40,000,000Mil mammograms yr USA, not including the rest of the world ( or the high dense breast incidents in Asia ), LLBO gets 10% = 4,000,000mil x *$150ea=Revenue of 600,000Mil & avg gross EBITDA profit of 45% =
about $270,000,000 Million,
Value Cyrcadia Health at 5X that profit =(270mil x 5= $1.5 Billion), So
LLBO PPS fair value (LLBO owns 30% of Cyrcadia or $450 Million) so 3.1bill OS share ($.145 PPS)
Now obviously something as big as breast cancer and the need for alternative solutions share price could fluctuate to higher levels on speculation ???
*($150-estimated annual iTBra fee per Cyrcadia)
Checked with El Camino hospital clinical trial site, study still closed, did not check OS cancer Inst., but was open last Nov when I posted their reply.
Regardless I do not believe the initial investor groups have changed: which I have re-posted below.
Clinical trial: Well let's look at what we do know versus total speculation.
The majority if not all of the original investors are still invested.
RB investments, Reno angel group, and The Propell group are still invested.
Most interesting is that the propell group likes to invest in companies that could be disruptive technology.
The angel group has a target of $100 million potential market to qualify for their capital outlay.
El Camino has closed the IT bra enrollment, and OSCCC is still open for enrollment.
Indications are that the Cyrcadia Breast Monitor has shown 82% or better efficacy.
All The above I do know
So have they or have they not filed for FDA approval, they had mentioned in the past
that FDA submittal would occur simultaneously ?
How soon will they make any kind of press release ?
Will they sell the company or look for further large VC investor ?
These things I don't know.
One last thing I forgot to mention is that one of several criteria other than $100 Mill mkt opportunity was that the Reno angel groups investment with any company had to have a clear exit strategy, which was that
The start up company had to be sold or significant investment by a VC, in other words they wanted their share of the pie immediately.
All of the information above took several hours of investigating online.
iTBra FDA Class ll:
FDA class II Substantially changed devices will need to be reviewed before marketing clearance will be issued by the fda...
(simply put can’t market the device due to device applied application time/ AI software changes are re approved )
Your Probably aware the iT Bra went through technology upgrades, these changes substantially changed the
efficacy for the better, but still need FDA review.
This is why their website states-“The product is not currently available for sale in the United States.“
& Cyrcadia Asia states ”FDA Class II clearance issued with further clearances in process.”
Will Covid-19 hasten or impede the FDA & US continued trial...will see !
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the Cyrcadia Breast Monitor -tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some Cyrcadia Breast Monitors...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
Post# 27171
PHd cancer researcher perspective Hint: U may be induced to buy more shares!
Post# 27131 PPS it’s long,but conclusion: pps.22 or more (updated per above $.14 PPS)
Post#27094 Co marketing intent: the short “it’s happening”!
Post# 27061 Market size & Need: Summary-It’s Huge & Needed
Post# 26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$ (Insurance CO’s want this money saving technology)
Post #27037 Number of breast cancer cases & importance of early detection: “Your life may depend on it”.
Post#26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
Post#25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
iFlytec(Keda Xunfei) & Cyrcadia Health
Bloomberg Nov, 2017 iFlytec video (6 months after iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted saying...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley office”
Read between the lines, LLBO S/B trading above .05 cents per share.
****************
Whole post I posted on 5/13/2020:
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
Fortune Business Insights:
Global | Published Date: Jul, 2019 | Report ID: FBI101065-
“The global telehealth market size valued at USD 49.8 Billion in 2018 and is projected to reach USD 266.8 Billion by 2026, exhibiting a CAGR of 23.4% between 2018 and 2026”
EBITDA valuation: for co’s up to $100Mil.Rev., is normally 5-7x EBITDA(Earnings before interest taxes depreciation and amortization)
40,000,000Mil mammograms yr USA, not including the rest of the world ( or the high dense breast incidents in Asia ), LLBO gets 10% = 4,000,000mil x *$150ea=Revenue of 600,000Mil & avg gross EBITDA profit of 45% =
about $270,000,000 Million,
Value Cyrcadia Health at 5X that profit =(270mil x 5= $1.5 Billion), So
LLBO PPS fair value (LLBO owns 30% of Cyrcadia or $450 Million) so 3.1bill OS share ($.145 PPS)
Now obviously something as big as breast cancer and the need for alternative solutions share price could fluctuate to higher levels on speculation ???
*($150-estimated annual iTBra fee per Cyrcadia)
iTBra FDA Class ll:
FDA class II Substantially changed devices will need to be reviewed before marketing clearance will be issued by the fda...
(simply put can’t market the device due to device applied application time/ AI software changes are re approved )
Your Probably aware the iT Bra went through technology upgrades, these changes substantially changed the
efficacy for the better, but still need FDA review.
This is why their website states-“The product is not currently available for sale in the United States.“
& Cyrcadia Asia states ”FDA Class II clearance issued with further clearances in process.”
Will Covid-19 hasten or impede the FDA & US continued trial...will see ! iFlytec(Keda Xunfei) & Cyrcadia Health
post# 27374
Re-Post: New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Bloomberg Nov, 2017 iFlytec video (6 months After Cyrcadia Asia iT Bra investment)
“China’s iFlytec focuses on smart healthcare” quoted...
—“Smart Healthcare growth (acquisition) is the primary Company smart tech strategic focus”
—Assisted diognostic system accuracy for improved cancer diognosis through AI imaging”
—“Out International strategy of investing in USA Co’s WILL assist this goal”
—Activities are being conducted at our new Silicon Valley...
Read between the lines, LLBO S/B trading above .05 cents per share.
Sent 5/14/20
Hi Jim,
Will you be explaining what has happened to Lifeline Biotechnologies percentage share ownership of about 45% of Cyrcadia Health to 30% ?
(As well as what has happened to the 15% equity)
I’m glad to see testing still on going at El Camino Hospital, hopefully
FDA will approve the changes soon.
Thank you Jim
Mike DeMunbrun
Investor
El Camino Hospital:
Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System
Services menu
* Clinical Trials
Phase: Pilot/Feasibility
Status: 1/2021 Recruiting
(pilot studies are not usually analytical trials designed to test a hypothesis (e.g., that the product performance exceeds that of a competitor). Instead, they usually focus on gathering data for use in optimizing the design of “subsequent clinical researchor device modifications.”)
—The purpose of this study is to determine if the Cyrcadia device can predict if a woman has breast cancer or benign breast tissue. The Cyrcadia device includes two adhesive patches with electrodes that are fitted over each breast. It collects data on the dynamic temperature changes in the breasts over time and transfers acquired data to a processing location which will return results to your physician. To determine the accuracy of this device, it will be tested on a group of women who have been scheduled for a breast biopsy due to a suspicious imaging test.
Principal Investigator
Shiva Singhal, MD
Sponsor
Cyrcadia, Inc.
NCT Number
NCT02511301
Contact
Kara Turner, Clinical Research Coordinator
Taft Center for Clinical Research
650-962-4562
Kara_Turner@elcaminohealth.org
For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.
((Other endpoints of the study are:
* to determine the accuracy of Cyrcadia CBR™, including the positive predictive value, negative predictive value, false negative rate and false positive rate.
* to determine the optimal wear time for the Cyrcadia CBR™.
* to demonstrate substantial equivalent or improved results when applied to Cyrcadia original patient case study with identical ANN-advanced neural network analysis computational results.
Study subjects will be followed at 6, 12, 18, and 24 months to update their clinical status.
Study Design
(Clinical Trial)
Estimated Enrollment :
173 participants
Primary Purpose:
Screening
Official Title:
Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System
Study Start Date :
June 2015
Estimated Primary Completion Date :
February 2020
Estimated Study Completion Date :
February 2020))
Jan 29,2021
Post on
Interesting nurse Barb & Cyrcadia LLBO Board member( Shyamali Mallick Singhal, Medical Director El Camino Cancer Center-MD, PhD, FACS ) work at El Camino where the CMD formally iT Bra pilot study (reconfirming ANN -AI artificial intelligence modified algorithm) can improve end specificity results ...((“Further refinement of the neural net algorithm”(ANN- foundation of artificial intelligence (AI) and solves problems that would prove impossible or difficult by human or statistical standards. ANNs have self-learning capabilities that enable them to produce better results as “more data becomes available”. (This is why Cyrcadia is building the largest breast data -data base, as they have previously mentioned- “transferred to a global cancer library where advanced analytical analysis occurs” ) is required in order to shorten the period of data recording and improve “specificity.”
)Principal Investigator
Shiva Singhal, MD
Sponsor
Cyrcadia, Inc.) recognize the name !
Certainly sounds like as previously quoted by past researchers as Disruptive Technology...tic toc
Abstracts tying into each other, the noose tightens, the dice roll Sep, 2020
2020 Sep
Abstract:
“An introduction to the Cyrcadia Breast Monitor: A wearable breast health monitoring device”
Vinitha Sree S et al. Comput Methods Programs Biomed. 2020 Dec.
excerpt: A pilot study of 173 female study subjects is underway, in order to validate this predictive model in an independent test population.
((On Cyrcadia board: Shyamali Mallick Singhal, Medical Director El Camino Cancer Center-MD, PhD, FACS ))
2009
Abstract: “Comparative study on the use of analytical software to identify the different stages of breast cancer using discrete temperature data”
excerpt: “Based on these evaluations, this current effort shows the feasibility of applying analytical software techniques together with the real-time functional thermal analysis to develop a potential tool for the detection and classification of breast cancer 2009”
Joanna M Y Tan et al. J Med Syst. 2009 Apr. Authors
Joanna M Y Tan 1 , E Y K Ng, Rajendra U Acharya, Louis G Keith, Jim Holmes
2006
Abstract: “The potential role of dynamic thermal analysis in breast cancer detection”
M Salhab et al. Int Semin Surg Oncol. 2006.
14: Salhab M, Al Sarakbi W, Mokbel K. The evolving role of the dynamic thermal analysis in the early detection of breast cancer. Int Semin Surg Oncol. 2005;2:8. doi: 10.1186/1477-7800-2-8. - DOI - PMC - PubMed
excerpt-
“The Future:
Dynamic thermal analysis of the breast is a safe, non invasive approach that seems to be sensitive for the early detection of breast cancer especially in young women where the conventional mammography is of limited value. Such a technology could become the initial breast screening test in pre-menopausal women and those who are classified as positive can then be selected for anatomical imaging with mammography, MRI and/or ultrasonography. “Further refinement of the neural net algorithm”(ANN- foundation of artificial intelligence (AI) and solves problems that would prove impossible or difficult by human or statistical standards. ANNs have self-learning capabilities that enable them to produce better results as “more data becomes available”. (This is why Cyrcadia is build the largest breast data data base, as they have previously mentioned- “transferred to a global cancer library where advanced analytical analysis occurs” ) is required in order to shorten the period of data recording and improve specificity. Prospective multi-centre trials are then required to validate these promising observations.”
So as I’ve posted long before, the advanced Algorithms (ANN) will prove pivotal in this study end results, will the FDA sneeze at this disruptive technology, some day the dice will stop rolling...
(From my previous PPS post:
5/13/2020:
PPS—$.14 Price Per Share (updated from my 2018 PPS analysis & updated LLBO Cyrcadia Health percentage ownership!)
It’s been a long long road to follow, with many curves, but the story line builds to a much needed product that works, where others don’t. Unfortunately most investors want to know the story, but only have the patience (or laziness to do no research) to wait for a fast food burger/fries with a Diet Coke (I like rum & cokes :)... !!! 13
Done
